Previous 10 | Next 10 |
2024-02-07 07:01:21 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Neurocrine Biosciences Q4 2023 Earnings Preview Bristol-Karuna deal: What other biotechs might be in M&A crosshairs? Seeking Alpha’s Quant Rating on Neur...
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2023 Financial Results and Provides Financial Expectations for 2024 PR Newswire INGREZZA ® (valbenazine) Fourth Quarter and Full Year 2023 Net Product Sales of $500 Million and $1.84 Billion , Represen...
Penske Automotive Group Inc. (PAG) is expected to report $3.66 for Q4 2023 Copa Holdings S.A. Class A (CPA) is expected to report $3.9 for Q4 2023 Wynn Resorts Limited (WYNN) is expected to report $1.12 for Q4 2023 U-Haul Holding Co Com (UHAL) is expected to report $0.82 for Q3 2024 ...
2024-02-06 13:15:43 ET More on Neurocrine Biosciences Neurocrine Biosciences: Fear Not The IRA Bristol-Karuna deal: What other biotechs might be in M&A crosshairs? Citi starts Neurocrine at neutral, sees stock as fairly valued Seeking Alpha’s Quant...
2024-01-28 12:00:53 ET More on Amgen, Vertex Pharma, etc. Biotech And Pharma Diversification Pays Off Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar...
2024-01-23 09:45:02 ET RBC Capital analyst issues UNDERPERFORM recommendation for NBIX on January 23, 2024 10:00AM ET. The previous analyst recommendation was Underperform. NBIX was trading at $140.505 at issue of the analyst recommendation. The overall analyst consensus...
2024-01-23 09:45:02 ET Wells Fargo analyst issues MARKET PERFORM recommendation for NBIX on January 23, 2024 10:00AM ET. The previous analyst recommendation was Market Perform. NBIX was trading at $140.505 at issue of the analyst recommendation. The overall analyst conse...
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2023 Financial Results PR Newswire Conference Call and Webcast Scheduled for Wednesday, February 7 SAN DIEGO , Jan. 17, 2024 /PRNewswire/ -- Neurocrine Bioscie...
2024-01-16 11:49:56 ET More on iShares Russell 1000 Growth ETF: IWF: Price Isn't Everything; Favor Growth Over Value Citi’s 30 stocks for its 2024 top themes Top overweight stocks with high growth and low volume - MS Seeking Alpha’s Quant Rating...
2024-01-04 14:57:40 ET More on SPDR S&P Biotech ETF: Biopharmaceutical Stocks: The Rally Has Just Begun Get Ready For The New Biotech Bull Market Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biotechs p...
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
2024-04-24 15:15:12 ET Wells Fargo analyst issues OVERWEIGHT recommendation for NBIX on April 23, 2024 04:12PM ET. The previous analyst recommendation was Buy. NBIX was trading at $139.345 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
Neurocrine Biosciences Launches WHAT THE C@H?! Educational Initiative to Support Congenital Adrenal Hyperplasia Community PR Newswire WHAT THE C@H?! provides a platform for the congenital adrenal hyperplasia (CAH) community to find educational information, share...
Neurocrine Biosciences Inc (NASDAQ:NBIX) revealed on Tuesday topline data for its Phase 2 SAVITRI study of NBI-1065845 in adult subjects with maj...